Literature DB >> 18417044

Early detection of liver cancer: diagnosis and management.

Michael L Volk1, Jorge A Marrero.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer deaths worldwide, and the incidence is rising. Despite a wide array of treatment options, fewer than half of candidates for potentially curative treatments receive them. The diagnosis and management of HCC require a multidisciplinary approach involving various clinical specialties. The foundation of diagnosis is high-quality imaging, with MRI being the test of choice. Some patients also require guided biopsy when MRI is equivocal. Treatment options depend upon the tumor stage and the degree of underlying synthetic dysfunction. Potentially curative treatments include surgical resection and transplantation. Other treatments that prolong survival include percutaneous ablation and transarterial chemoembolization. A new oral agent, sorafenib, was recently shown to prolong survival in patients with advanced HCC. By increasing surveillance and treatment of HCC, outcomes for these patients may be improved.

Entities:  

Mesh:

Year:  2008        PMID: 18417044     DOI: 10.1007/s11894-008-0010-2

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  42 in total

1.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Authors:  Jorge A Marrero; Hero K Hussain; Hahn V Nghiem; Ramsey Umar; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

2.  A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  L Lladó; J Virgili; J Figueras; C Valls; J Dominguez; A Rafecas; J Torras; J Fabregat; J Guardiola; E Jaurrieta
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

3.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

4.  Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique.

Authors:  Katherine E Maturen; Hanh V Nghiem; Jorge A Marrero; Hero K Hussain; Ellen G Higgins; Giovanna A Fox; Isaac R Francis
Journal:  AJR Am J Roentgenol       Date:  2006-11       Impact factor: 3.959

5.  Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Hadni-Bresson; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Laurent Sulpice; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges-Philippe Pageaux; Sebastien Dharancy; Olivier Chazouilleres; Daniel Cherqui; Christophe Duvoux
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

6.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

7.  The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996.

Authors:  W G Cance; A K Stewart; H R Menck
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

8.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

9.  Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients.

Authors:  T Kaizu; K Karasawa; Y Tanaka; T Matuda; H Kurosaki; S Tanaka; T Kumazaki
Journal:  Am J Gastroenterol       Date:  1998-11       Impact factor: 10.864

Review 10.  Treatment of HCC in patients awaiting liver transplantation.

Authors:  M Schwartz; S Roayaie; P Uva
Journal:  Am J Transplant       Date:  2007-05-26       Impact factor: 8.086

View more
  8 in total

1.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

2.  Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations.

Authors:  A Ruth He; Alec S Goldenberg
Journal:  Therap Adv Gastroenterol       Date:  2013-11       Impact factor: 4.409

3.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Thomas A Abrams; Steven R Alberts; Daniel Anaya Saenz; Chandrakanth Are; Daniel B Brown; Daniel T Chang; Anne M Covey; William Hawkins; Renuka Iyer; Rojymon Jacob; Andrea Karachristos; R Kate Kelley; Robin Kim; Manisha Palta; James O Park; Vaibhav Sahai; Tracey Schefter; Carl Schmidt; Jason K Sicklick; Gagandeep Singh; Davendra Sohal; Stacey Stein; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Andrew X Zhu; Karin G Hoffmann; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

4.  Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival.

Authors:  Tammy T Chang; Rajiv Sawhney; Alexander Monto; J Ben Davoren; Jacob G Kirkland; Lygia Stewart; Carlos U Corvera
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

5.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

6.  Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model.

Authors:  S Ke; F Zhang; W Wang; X Qiu; J Lin; A G Cameron; C Zou; X Gao; C Zou; V F Zhu; M Li
Journal:  Curr Mol Med       Date:  2012-09       Impact factor: 2.222

7.  TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.

Authors:  Dae-Won Lee; Myoung-Jin Jang; Kyung-Hun Lee; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Tae-Yong Kim; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim
Journal:  Br J Cancer       Date:  2016-10-13       Impact factor: 7.640

Review 8.  Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

Authors:  Jennifer Eatrides; Emilie Wang; Nishi Kothari; Richard Kim
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.